Johnson & Johnson stock pre-market at EUR 236.43: plus 0.36 percent
Published on 09/30/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock is at EUR 236.43 pre-market at Lang & Schwarz as of 7:51 a.m. CEST on September 30, 2026. The price is up 0.36 percent versus the Lang & Schwarz prior close of EUR 235.58.
IMAAVY data released
Johnson & Johnson said on September 29 that it had presented new findings on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis across 15 abstracts scheduled for presentation at the 2026 Myasthenia Gravis Foundation of America Scientific Session and the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. The company said two-year findings from the Phase 2/3 Vibrance-MG long-term extension study showed sustained disease control in adolescents with anti-AChR-positive gMG, alongside improvements in daily function and muscle strength and reductions in corticosteroid use. Johnson & Johnson reported that mean changes from baseline at Week 108 were minus 2.88 points on the MG-ADL measure and minus 8.25 points on the QMG measure among participants with available data.
Earlier CAPLYTA findings
In a September 21 release, Johnson & Johnson said CAPLYTA (lumateperone) significantly reduced signs and symptoms of acute manic episodes associated with bipolar I disorder as early as Day 3, with benefits sustained through Week 3. The company described the findings as results from a pivotal Phase 3 study. Johnson & Johnson published the release on its press-release page.
